14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
FDMT vs BMRN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, BioMarin Pharmaceuticals Inc (BMRN) is the stronger overall head-to-head candidate over 4D Molecular Therapeutics, Inc. (FDMT) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). FDMT carries a Unified Composite Score of 42.1/100 (HOLD) at $11.65 (N/M Forward P/E, -222.7% operating margin), whereas BMRN carries 52.3/100 (HOLD) at $58.32 (9.1x Forward P/E, 16.3% operating margin).
Growth vs. Quality Trade-Off: BMRN earns the overall head-to-head edge with a stronger Unified Composite Score (52.3/100 HOLD vs. FDMT 42.1/100 HOLD) and 0.28β · 31% Vol risk profile, whereas FDMT leads top-line expansion (+4505.6% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: FDMT is currently in a Breakdown options structure phase (RSI 46.9); meanwhile BMRN trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 54.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Biotechnology value chain with $11.0B market capitalization and 16.3% operating margin.
OpEx & R&D Reinvestment36.9% of Rev ($1.35B)
90D Engineering Disclosures0 Published
Investor FAQ FDMT vs BMRN Key Questions & Quantitative Answers
As of Nov 16, 2026, BioMarin Pharmaceuticals Inc (BMRN) is the stronger overall head-to-head candidate over 4D Molecular Therapeutics, Inc. (FDMT) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). FDMT carries a Unified Composite Score of 42.1/100 (HOLD) at $11.65 (N/M Forward P/E, -222.7% operating margin), whereas BMRN carries 52.3/100 (HOLD) at $58.32 (9.1x Forward P/E, 16.3% operating margin). Growth vs. Quality Trade-Off: BMRN earns the overall head-to-head edge with a stronger Unified Composite Score (52.3/100 HOLD vs. FDMT 42.1/100 HOLD) and 0.28β · 31% Vol risk profile, whereas FDMT leads top-line expansion (+4505.6% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: FDMT is currently in a Breakdown options structure phase (RSI 46.9); meanwhile BMRN trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 54.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
FDMT leads the Growth & Scale pillar: FDMT posts +4505.6% YoY revenue growth and +0.0% YoY earnings growth on $96M TTM revenue (N/A gross margin, -222.7% operating margin), compared with BMRN at +32.0% YoY revenue growth and -81.3% YoY earnings growth on $3.66B TTM revenue (53.2% gross margin, 16.3% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), FDMT cumulative revenue shifted +800.0% while BMRN shifted +116.1%. In operating R&D and SG&A reinvestment, FDMT deploys N/A (0 90-day corporate R&D disclosures) versus 36.9% of Rev ($1.35B) (0 disclosures) for BMRN.
BMRN screens cheaper on headline valuation multiples. FDMT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.6x EV/Revenue (unreported FCF margin), whereas BMRN trades at 9.1x Forward P/E, 8.8x Trailing P/E, 0.34x PEG, and 3.9x EV/Revenue (15.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FDMT (-56.7% ROE) versus BMRN (-0.3% ROE) capital efficiency.
In options market volatility and institutional positioning, FDMT carries 82.4% implied volatility (10th %ile, Compressed (<25th %ile)), a 5.16x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.89β · 90% Vol realized risk). By comparison, BMRN carries 37.4% implied volatility (17th %ile, Compressed (<25th %ile)), a 0.06x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.28β · 31% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.